MTEM - Molecular Templates, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.69
-0.47 (-4.21%)
At close: 4:00PM EST

10.37 -0.32 (-2.99%)
After hours: 6:31PM EST

Stock chart is not supported by your current browser
Previous Close11.16
Open11.14
Bid10.67 x 800
Ask10.62 x 900
Day's Range10.36 - 11.43
52 Week Range3.19 - 14.05
Volume171,843
Avg. Volume254,140
Market Cap469M
Beta (5Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-1.64
Earnings DateAug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
  • GlobeNewswire

    Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

    AUSTIN, Texas, Dec. 09, 2019 -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s.

  • In the money Dec. 2: $49M reported raised
    American City Business Journals

    In the money Dec. 2: $49M reported raised

    Check out the latest fundings for Austin companies, including a deal that could be worth more than $500 million for a biotech firm. There's also another seltzer maker in town, spurred on by the founder of Big Ass Fans.

  • GlobeNewswire

    Molecular Templates to Present at Two December Investor Conferences

    AUSTIN, Texas, Nov. 26, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s.

  • GlobeNewswire

    Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

    Molecular Templates, Inc. (MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share. Each share of Series A convertible preferred stock will be convertible into 1,000 shares of common stock at the holder’s option, subject to beneficial ownership limitations. All of the shares of common stock and Series A convertible preferred stock to be sold in the offering are being sold by Molecular.

  • GlobeNewswire

    Molecular Templates, Inc. Announces Proposed Public Equity Offering

    Molecular Templates, Inc. (MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that it has commenced an underwritten public offering of its common stock and newly designated Series A convertible preferred stock. Molecular also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by Molecular.

  • GlobeNewswire

    Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

    Vertex Pharmaceuticals Incorporated (VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001. CTX001 is currently being evaluated in two ongoing Phase 1/2 studies in patients with transfusion-dependent beta thalassemia and severe sickle cell disease, where a hematopoietic stem cell transplant is required as part of treatment with CTX001.

  • GlobeNewswire

    Translational Research in Oncology (TRIO) Initiates Phase I Study for MT-5111

    EDMONTON, Alberta, Nov. 14, 2019 -- Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrolment of the first patient.

  • GlobeNewswire

    Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

    AUSTIN, Texas, Nov. 12, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on.

  • GlobeNewswire

    Molecular Templates Hosting Analyst & Investor Meeting

    Molecular Templates, Inc. (MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, announced today that it will host an analyst & investor breakfast on November 15th from 8:00am to 10:00am ET in New York City. The meeting will feature presentations by Key Opinion Leaders (KOLs) Matthew McKinney, MD, from Duke University, and Zev Wainberg, MD, from UCLA, who will discuss the current treatment landscape and unmet medical need in treating patients with diffuse large B-cell lymphoma and HER2-positive cancers, respectively. Additionally, John Newcomb, PhD, Director in the Immuno-Oncology Drug Discovery Unit at Takeda Pharmaceuticals, will discuss partnered asset TAK-169, a 2nd generation de-immunized ETB targeting CD38 in multiple myeloma.

  • What Kind Of Shareholders Own Molecular Templates, Inc. (NASDAQ:MTEM)?
    Simply Wall St.

    What Kind Of Shareholders Own Molecular Templates, Inc. (NASDAQ:MTEM)?

    If you want to know who really controls Molecular Templates, Inc. (NASDAQ:MTEM), then you'll have to look at the...

  • GlobeNewswire

    Molecular Templates to Present at the Ladenburg Thalmann and Cantor Fitzgerald Healthcare Conferences

    AUSTIN, Texas, Sept. 23, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s.

  • Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?
    Simply Wall St.

    Is Molecular Templates (NASDAQ:MTEM) Using Too Much Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    Molecular Templates, Inc. Reports Second Quarter 2019 Financial Results

    AUSTIN, Texas, Aug. 12, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on.

  • Analysts Estimate Molecular Templates (MTEM) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Molecular Templates (MTEM) to Report a Decline in Earnings: What to Look Out for

    Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Molecular Templates (NASDAQ:MTEM) Shareholders Have Enjoyed A 52% Share Price Gain
    Simply Wall St.

    Molecular Templates (NASDAQ:MTEM) Shareholders Have Enjoyed A 52% Share Price Gain

    Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...

  • Did Hedge Funds Drop The Ball On Molecular Templates, Inc. (MTEM) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Molecular Templates, Inc. (MTEM) ?

    The first quarter was a breeze as Powell pivoted, and China seemed eager to reach a deal with Trump. Both the S&P 500 and Russell 2000 delivered very strong gains as a result, with the Russell 2000, which is composed of smaller companies, outperforming the large-cap stocks slightly during the first quarter. Unfortunately sentiment shifted […]

  • GlobeNewswire

    Molecular Templates Announces FDA Acceptance of IND Application for TAK-169, An Engineered Toxin Body Targeting CD38

    Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular,” “Molecular Templates” or “MTEM”) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for TAK-169, an ETB targeting CD38. MTEM and partner Takeda Pharmaceutical Company Limited (Takeda) are co-developing TAK-169 and plan to conduct an open label Phase I dose escalation and expansion study in relapsed/refractory multiple myeloma patients. “We are excited to continue our collaboration with Takeda advancing the development of TAK-169 for the treatment of multiple myeloma patients,” said Eric Poma, Ph.D., CEO and CSO of Molecular Templates.

  • Will Molecular Templates to Surge Higher?
    Zacks

    Will Molecular Templates to Surge Higher?

    As of late, it has definitely been a great time to be an investor Molecular Templates.

  • GlobeNewswire

    Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference

    AUSTIN, Texas, May 14, 2019 -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin.

  • GlobeNewswire

    Molecular Templates, Inc. Reports First Quarter 2019 Financial Results

    AUSTIN, Texas, May 13, 2019 -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and.

  • Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Molecular Templates (MTEM) Report Negative Q1 Earnings? What You Should Know

    Molecular Templates (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    The Judge Group Named a Winner of the Delaware Valley 2019 Top Workplaces Award by Philadelphia Media Network

    The Judge Group, a leading global professional services firm, has been awarded a 2019 Top Workplaces honor by Philadelphia Media Network. The award is based solely on employee feedback gathered through a third-party survey administered by research partner Energage, LLC (formerly WorkplaceDynamics), a leading provider of technology-based employee engagement tools. The anonymous survey measures several aspects of workplace culture, including alignment, execution, and connection, just to name a few.

  • GlobeNewswire

    Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2

    Molecular Templates, Inc., (MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for MT-5111, an ETB targeting HER2. MT-5111 specifically binds and kills HER2 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity.

  • The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
    Zacks

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

  • Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
    Zacks

    Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

    Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.